Trial Profile
A Phase 1/2, Randomized, Observer-Blinded, Active-Controlled Trials to Evaluate the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix-M1 Adjuvant (NanoFlu) in Healthy Older Adults
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Dec 2022
Price :
$35
*
At a glance
- Drugs NanoFlu vaccine-Novavax (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Novavax
- 11 Mar 2019 Status changed from active, no longer recruiting to completed.
- 13 Jun 2018 According to Novavax media release, data from this trial was published in the New England Journal of Medicine (NEJM).
- 13 Jun 2018 Results presented in the Novavax media release.